1H-Indole-2,4-dione, 3-[2,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]-3,5,6,7-tetrahydro-6,6-dimethyl-1-phenyl-3-(trifluoromethyl)- manufacturers
- ELOVL6-IN-2
-
- $33.00
-
2026-08-30
- CAS:1067647-43-1
- Purity: 99.95%
- Supply Ability: 10g
|
| | 1H-Indole-2,4-dione, 3-[2,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]-3,5,6,7-tetrahydro-6,6-dimethyl-1-phenyl-3-(trifluoromethyl)- Basic information |
| Product Name: | 1H-Indole-2,4-dione, 3-[2,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]-3,5,6,7-tetrahydro-6,6-dimethyl-1-phenyl-3-(trifluoromethyl)- | | Synonyms: | 6,6-Dimethyl-3-(5-methyl-3-oxo-2-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-pyr zol-4-yl)-1-phen;6,6-Dimethyl-3-(5-methyl-3-oxo-2-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-pyrzol-4-yl)-1-ph;6,6-Dimethyl-3-(5-methyl-3-oxo-2-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-pyrzol-4-yl)-1-phenyl-3-(trifluoromethyl)-6,7-dihydro-1H-indole-2,4(3H,5H)-dione;ELOVL6-IN-2;6,6-Dimethyl-3-(5-methyl-3-oxo-2-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-pyrazol-4-yl)-1-phenyl-3-(trifluoromethyl)-6,7-dihydro-1H-indole-2,4(3H,5H)-dione;ELOVL6IN2,ELOVL6 IN 2,plasma,inhibit,selective,ELOVL-6-IN-2,liver,dose-proportionally,Inhibitor,potent,orally;ELOVL6-IN-2, 10 mM in DMSO;1H-Indole-2,4-dione, 3-[2,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]-3,5,6,7-tetrahydro-6,6-dimethyl-1-phenyl-3-(trifluoromethyl)- | | CAS: | 1067647-43-1 | | MF: | C28H23F6N3O4 | | MW: | 579.49 | | EINECS: | | | Product Categories: | | | Mol File: | 1067647-43-1.mol | ![1H-Indole-2,4-dione, 3-[2,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]-3,5,6,7-tetrahydro-6,6-dimethyl-1-phenyl-3-(trifluoromethyl)- Structure](CAS/GIF/1067647-43-1.gif) |
| | 1H-Indole-2,4-dione, 3-[2,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]-3,5,6,7-tetrahydro-6,6-dimethyl-1-phenyl-3-(trifluoromethyl)- Chemical Properties |
| Boiling point | 609.6±65.0 °C(Predicted) | | density | 1.49±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO : 100 mg/mL (172.57 mM; Need ultrasonic) | | pka | -1.24±0.70(Predicted) | | form | Solid | | color | White to off-white |
| | 1H-Indole-2,4-dione, 3-[2,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]-3,5,6,7-tetrahydro-6,6-dimethyl-1-phenyl-3-(trifluoromethyl)- Usage And Synthesis |
| Uses | ELOVL6-IN-2 is a potent, orally active and selective ELOVL6 inhibitor. ELOVL6-IN-2 inhibits mouse ELOVL6 activities, with an IC50 value of 34 nM[1]. | | in vivo | ELOVL6-IN-2 (0.1~1mg/kg; p.o.; 2 hours) potently and dose-proportionally suppresses the elongation index in the liver[1].
ELOVL6-IN-2 (10mg/kg; p.o.; 2 hours) demonstrates highly liver penetrable[1].
ELOVL6-IN-2 (1mg/kg; p.o.; 2~24 hours) exhibits sustained plasma exposure[1]. | Animal Model: | Male C57BL/6J mice | | Dosage: | 0.1~1mg/kg | | Administration: | P.o | | Result: | Potently and dose-proportionally suppressed the elongation index in the liver.
|
| Animal Model: | Male C57BL/6J mice | | Dosage: | 10 mg/kg | | Administration: | P.o | | Result: | Demonstrated highly liver penetrable.
|
| Animal Model: | Male C57BL/6J mice | | Dosage: | 1 mg/kg | | Administration: | P.o | | Result: | Exhibited sustained plasma exposure.
|
| | References | [1] akahashi T, et al. Synthesis and evaluation of a novel indoledione class of long chain fatty acid elongase 6 (ELOVL6) inhibitors. J Med Chem. 2009;52(10):3142-3145. DOI:10.1021/jm900391x |
| | 1H-Indole-2,4-dione, 3-[2,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]-3,5,6,7-tetrahydro-6,6-dimethyl-1-phenyl-3-(trifluoromethyl)- Preparation Products And Raw materials |
|